Immutep and MSD Join Forces for KEYTRUDA Combination Trial
Sunday, 2 June 2024, 21:48
Immutep Announces Clinical Collaboration with MSD
Immutep has made a groundbreaking announcement regarding a clinical collaboration with MSD to evaluate Efti in combination with KEYTRUDA in a pivotal Phase III trial. This collaboration underscores the companies' commitment to advancing cancer treatment through innovative research and development efforts.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.